Railroad between Cusco and Machu Picchu at Aguas Calientes in Peru

Hikma Launches Ustekinumab Biosimilar STARJEMZA

Start
On November 6, 2025, Hikma Pharmaceuticals PLC, and its subsidiary Hikma Pharmaceuticals USA Inc., announced the launch of STARJEMZA (ustekinumab-hmny).  STARJEMZA references Janssen’s STELARA, and is indicated for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis….
By: Goodwin
Previous Story

CMS Finalizes Changes to Bona Fide Service Fee Requirements, Alongside Other Adjustments to Medicare Part B Drug Reimbursement Methodology

Next Story

New National Guidance Lays Out ‘Responsible Use of AI’ for Healthcare Industry